A detailed history of Two Sigma Investments, LP transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 81,380 shares of KRON stock, worth $76,497. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,380
Previous 132,320 38.5%
Holding current value
$76,497
Previous $172,000 41.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.73 - $1.38 $37,186 - $70,297
-50,940 Reduced 38.5%
81,380 $100,000
Q1 2024

May 15, 2024

SELL
$1.02 - $1.3 $6,010 - $7,660
-5,893 Reduced 4.26%
132,320 $172,000
Q4 2023

Feb 14, 2024

SELL
$0.75 - $1.49 $46,443 - $92,268
-61,925 Reduced 30.94%
138,213 $172,000
Q3 2023

Nov 14, 2023

SELL
$1.23 - $2.25 $107,000 - $195,732
-86,992 Reduced 30.3%
200,138 $260,000
Q2 2023

Aug 14, 2023

BUY
$1.24 - $1.92 $155,605 - $240,936
125,488 Added 77.63%
287,130 $493,000
Q1 2023

May 15, 2023

SELL
$1.34 - $2.62 $44,447 - $86,905
-33,170 Reduced 17.03%
161,642 $235,000
Q4 2022

Feb 14, 2023

SELL
$1.44 - $3.44 $67,455 - $161,143
-46,844 Reduced 19.38%
194,812 $315,000
Q3 2022

Nov 14, 2022

SELL
$3.35 - $5.55 $405,205 - $671,311
-120,957 Reduced 33.36%
241,656 $810,000
Q2 2022

Aug 15, 2022

BUY
$3.12 - $7.52 $913,242 - $2.2 Million
292,706 Added 418.71%
362,613 $1.32 Million
Q1 2022

May 16, 2022

BUY
$6.26 - $14.42 $105,862 - $243,856
16,911 Added 31.91%
69,907 $505,000
Q4 2021

Feb 14, 2022

BUY
$11.35 - $21.18 $373,426 - $696,843
32,901 Added 163.73%
52,996 $720,000
Q3 2021

Nov 15, 2021

BUY
$18.17 - $24.7 $365,126 - $496,346
20,095 New
20,095 $421,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $53.4M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.